Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 1.7 %

BTX opened at $6.33 on Friday. The stock’s 50 day simple moving average is $3.87 and its 200-day simple moving average is $1.84. The stock has a market cap of $372.37 million, a PE ratio of -2.79 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1 year low of $6.22 and a 1 year high of $8.31.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.